Filing Flows › Procept BioRobotics (PRCT) › Q1 2026
Procept BioRobotics (PRCT) Q1 2026 earnings results (first quarter 2026)
10-Q filed Apr 30, 2026
Procept BioRobotics (PRCT) reported revenue of $83.1M for the first quarter 2026 (Q1 2026), +20% from a year earlier and +9% from the quarter before. Operating margin was -39.2%, net loss $31.6M (38.1% of revenue).
Procept BioRobotics, Q1 2026: revenue $83.1M (+20% year over year), operating margin -39.2%, net loss $31.6M, operating cash flow −$38.1M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $83.1M | +9% | +20% |
| Operating profit | −$32.6M | — | — |
| Net earnings | −$31.6M | — | — |
| Operating cash flow | −$38.1M | — | — |
What changed
Revenue was $83.1M in Q1 2026, up 20% year over year and up 9% from the previous quarter.
Gross margin was 64.9%, up 1.0 points from Q1 2025. Operating costs exceeded revenue by $32.6M, an operating margin of -39.2%. Operating expenses grew 21% against revenue growth of 20%. The fastest-growing cost line was Research & development (+31%). The quarter ended with a net loss of $31.6M, wider than the previous quarter's $29.8M loss.
Operating cash flow was −$38.1M. Non-cash charges added back $1.7M of depreciation and amortization and $13.1M of share-based compensation. Working capital and other items used $21.3M. Capital expenditures of $2.9M exceeded it, leaving free cash flow of −$41.0M.
Questions
What was Procept BioRobotics' revenue in the first quarter 2026?
Procept BioRobotics (PRCT) reported revenue of $83.1M for the first quarter 2026 (Q1 2026), +20% from a year earlier and +9% from the quarter before.
Was Procept BioRobotics profitable in the first quarter 2026?
Operating loss was $32.6M (-39.2% of revenue) and net loss $31.6M.